Madeline R. Sponholtz

Feb 10, 2024 | biorxiv.org | Patrick Byrne |Madeline R. Sponholtz |Alison Lee |Ajit R Ramamohan

AbstractHuman cytomegalovirus (HCMV) glycoprotein B (gB) is a class III membrane fusion protein required for viral entry. HCMV vaccine candidates containing gB have demonstrated moderate clinical efficacy, but no HCMV vaccine has been FDA-approved. Here, we used structure-based design to identify and characterize amino acid substitutions that stabilize gB in its metastable prefusion conformation.